Alicja Kuban-Jankowska1, Magdalena Gorska-Ponikowska2, Michal Wozniak2. 1. Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland alicjakuban@gumed.edu.pl. 2. Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland.
Abstract
BACKGROUND: Protein tyrosine phosphatases PTP1B and SHP2 are potential targets for anticancer therapy, because of the essential role they play in the development of tumors. PTP1B and SHP2 are overexpressed in breast cancer cells, thus inhibition of their activity can be potentially effective in breast cancer therapy. Lipoic acid has been previously reported to inhibit the proliferation of colon, breast and thyroid cancer cells. MATERIALS AND METHODS: We investigated the effect of alpha-lipoic acid (ALA) and its reduced form of dihydrolipoic acid (DHLA) on the viability of MCF-7 cancer cells and on the enzymatic activity of PTP1B and SHP2 phosphatases. RESULTS: ALA and DHLA decrease the activity of PTP1B and SHP2, and have inhibitory effects on the viability and proliferation of breast cancer cells. CONCLUSION: ALA and DHLA can be considered as potential agents for the adjunctive treatment of breast cancer. Copyright
BACKGROUND: Protein tyrosine phosphatases PTP1B and SHP2 are potential targets for anticancer therapy, because of the essential role they play in the development of tumors. PTP1B and SHP2 are overexpressed in breast cancer cells, thus inhibition of their activity can be potentially effective in breast cancer therapy. Lipoic acid has been previously reported to inhibit the proliferation of colon, breast and thyroid cancer cells. MATERIALS AND METHODS: We investigated the effect of alpha-lipoic acid (ALA) and its reduced form of dihydrolipoic acid (DHLA) on the viability of MCF-7 cancer cells and on the enzymatic activity of PTP1B and SHP2 phosphatases. RESULTS:ALA and DHLA decrease the activity of PTP1B and SHP2, and have inhibitory effects on the viability and proliferation of breast cancer cells. CONCLUSION:ALA and DHLA can be considered as potential agents for the adjunctive treatment of breast cancer. Copyright
Authors: Diana Farhat; Sophie Léon; Sandra E Ghayad; Nicolas Gadot; Philippe Icard; Muriel Le Romancer; Nader Hussein; Hubert Lincet Journal: Br J Cancer Date: 2020-01-28 Impact factor: 7.640